TY - JOUR
T1 - Total body irradiation-based haploidentical hematopoietic stem cell transplantation using posttransplant cyclophosphamide after administration of inotuzumab ozogamicin
T2 - A case report
AU - Abe, Masaya
AU - Fujii, Nobuharu
AU - Mizuhara, Kentaro
AU - Urata, Tomohiro
AU - Sumii, Yuichi
AU - Fujiwara, Yuki
AU - Seike, Keisuke
AU - Sando, Yasuhisa
AU - Nakamura, Makoto
AU - Fujii, Keiko
AU - Saeki, Kyosuke
AU - Meguri, Yusuke
AU - Asada, Noboru
AU - Ennishi, Daisuke
AU - Nishimori, Hisakazu
AU - Matsuoka, Ken ichi
AU - Maeda, Yoshinobu
N1 - Publisher Copyright:
© 2021 The Authors
PY - 2021/1
Y1 - 2021/1
N2 - Owing to the poor prognosis of relapsed or refractory acute lymphoblastic leukemia (ALL), hematopoietic stem cell transplantation (HSCT) followed by effective salvage therapy is required. Inotuzumab ozogamicin (INO) was developed for ALL refractory to standard chemotherapy. However, previous reports suggest that sinusoidal obstruction syndrome (SOS) risk increases in patients with HSCT receiving INO, especially with dual alkylating agents. We report a case of relapsed Philadelphia chromosome-negative B-ALL where the patient underwent haploidentical HSCT using fludarabine/total body irradiation conditioning and posttransplant cyclophosphamide. Successful engraftment was achieved without SOS development.
AB - Owing to the poor prognosis of relapsed or refractory acute lymphoblastic leukemia (ALL), hematopoietic stem cell transplantation (HSCT) followed by effective salvage therapy is required. Inotuzumab ozogamicin (INO) was developed for ALL refractory to standard chemotherapy. However, previous reports suggest that sinusoidal obstruction syndrome (SOS) risk increases in patients with HSCT receiving INO, especially with dual alkylating agents. We report a case of relapsed Philadelphia chromosome-negative B-ALL where the patient underwent haploidentical HSCT using fludarabine/total body irradiation conditioning and posttransplant cyclophosphamide. Successful engraftment was achieved without SOS development.
KW - Acute lymphoblastic leukemia
KW - Hematopoietic stem cell transplantation
KW - Inotuzumab ozogamicin
KW - Posttransplant cyclophosphamide
KW - Sinusoidal obstruction syndrome
UR - http://www.scopus.com/inward/record.url?scp=85104938042&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85104938042&partnerID=8YFLogxK
U2 - 10.1016/j.lrr.2021.100241
DO - 10.1016/j.lrr.2021.100241
M3 - Article
AN - SCOPUS:85104938042
SN - 2213-0489
VL - 15
JO - Leukemia Research Reports
JF - Leukemia Research Reports
M1 - 100241
ER -